28 Day infected vs. control
Gene Symbol Control Avg. Ct ±SEM Infected Avg. Ct ±SEM Fold change p‐value
Ccl24 12.79 ±0.76 10.62 ±0.53 4.5 0.007
Ccl3 10.18 ±0.54 7.81 ±1.00 5.5 0.025
Ccl4 9.03 ±0.59 6.28 ±0.44 6.7 0.036
Cd40lg 14.01 ±0.30 11.05 ±0.36 7.8 0.011
Cxcl1 9.00 ±0.25 6.18 ±0.24 7.1 0.028
Il22 15.96 ±0.37 15.03 ±0.39 1.9 0.024
35 day infected vs. control 
Bmp7 6.43 ±0.17 6.51 ±0.25 0.5 0.032
Csf3 4.88 ±0.05 5.47 ±0.06 0.5 <0.001
Ccl4 9.03 ±0.58 6.28 ±0.23 4.2 0.019
Ctf1 6.67 ±0.15 7.19 ±0.12 0.6 0.023
Hprt 1.65 ±0.14 1.81 ±0.04 0.6 0.022
Ifna2 11.3 ±0.19 11.41 ±0.24 0.4 0.014
Ifng 13.04 ±0.54 9.68 ±0.43 8.5 0.035
Il10 9.94 ±0.38 8.35 ±0.32 2.8 0.048
Il11 11.76 ±0.07 10.52 ±0.23 2.3 0.03
Il18 5.86 ±0.22 6.54 ±0.06 0.4 0.014
Il1a 7.13 ±0.09 5.97 ±0.04 1.4 0.007
Il1rn 6.36 ±0.37 5.95 ±0.13 1.9 0.042
Mif 0.43 ±0.12 0.76 ±0.08 0.7 0.045
Pf4 5.15 ±0.19 5.26 ±0.06 0.6 0.031
Thpo 12.95 ±0.6 13.76 ±0.16 3.7 0.019
Tnf 8.4 ±0.19 6.86 ±0.09 2.4 0.002
Table 1: Effect of treatment on the expression of mRNAs in the vagina at 28 and 35 days post‐infection.